These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 33408313)

  • 21. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
    Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
    Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of dipeptidyl peptidase-4 inhibitors is associated with a lower risk of rheumatoid arthritis in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of cohort studies.
    Charoenngam N; Rittiphairoj T; Ponvilawan B; Ungprasert P
    Diabetes Metab Syndr; 2021; 15(1):249-255. PubMed ID: 33465685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.
    Deacon CF
    Nat Rev Endocrinol; 2020 Nov; 16(11):642-653. PubMed ID: 32929230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Characteristics and Follow-Up of 19 Children With Hashimoto's Thyroiditis Aged Below 3 Years: A Single-Center Retrospective Analysis.
    Tang S; Yang M; Zhang D; Tong YJ; Xin Y
    Front Endocrinol (Lausanne); 2021; 12():737527. PubMed ID: 34539581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dipeptidyl peptidase-4 inhibitor treatment could decrease
    Chen HH; Chen CC; Ho CW; Hsieh MC; Hsu SP; Lin CL; Kao CH
    Postgrad Med; 2020 Nov; 132(8):714-719. PubMed ID: 32633173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of DPP4 inhibitors on the levels of plasma catecholamines and their metabolites in patients with type 2 diabetes.
    Kim TH; Lee K; Park IB; Choi CS; Ahn TH; Lee DH
    Diabetes Res Clin Pract; 2019 Oct; 156():107832. PubMed ID: 31513823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes.
    Bouchi R; Fukuda T; Takeuchi T; Nakano Y; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
    Diabetes Metab Res Rev; 2018 Feb; 34(2):. PubMed ID: 29054111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a population-based cohort study.
    Hou WH; Chang KC; Li CY; Ou HT
    Pain; 2016 Sep; 157(9):1954-1959. PubMed ID: 27127847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
    Cho YY; Cho SI
    Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bariatric surgery, novel glucose-lowering agents, and insulin for type 2 diabetes and obesity: Bayesian network meta-analysis of randomized controlled trials.
    Wu T; Wong CKH; Lui DTW; Wong SKH; Lam CLK; Chung MSH; McAllister DA; Welbourn R; Dixon JB
    BJS Open; 2023 Jul; 7(4):. PubMed ID: 37542473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Association of Joint Pain and Dipeptidyl Peptidase-4 Inhibitor Use Among U.S. Adults With Type-2 Diabetes Mellitus.
    Rai P; Zhao X; Sambamoorthi U
    J Pain Palliat Care Pharmacother; 2018; 32(2-3):90-97. PubMed ID: 30676844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.
    Kim SC; Glynn RJ; Liu J; Everett BM; Goldfine AB
    Acta Diabetol; 2014 Dec; 51(6):1015-23. PubMed ID: 25311055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DPP4 inhibitors as a potential therapeutic option for sarcopenia: A 6-month follow-up study in diabetic older patients.
    Sencan C; Dost FS; Ates Bulut E; Isik AT
    Exp Gerontol; 2022 Jul; 164():111832. PubMed ID: 35526704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postpartum Thyroiditis in Women With Euthyroid and Hypothyroid Hashimoto's Thyroiditis Antedating Pregnancy.
    Moleti M; Mauro MD; Alibrandi A; Vita R; Benvenga S; Vermiglio F
    J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32301483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Seong JM; Yee J; Gwak HS
    Br J Clin Pharmacol; 2019 Aug; 85(8):1719-1727. PubMed ID: 30964554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
    Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
    Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
    Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
    Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between deterioration of glycated hemoglobin-lowering effects in dipeptidyl peptidase-4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes.
    Kuwata H; Okamoto S; Seino Y; Murotani K; Tatsuoka H; Usui R; Hamamoto Y; Kurose T; Seino Y; Yabe D
    J Diabetes Investig; 2018 Sep; 9(5):1153-1158. PubMed ID: 29172255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment.
    Yin R; Xu Y; Wang X; Yang L; Zhao D
    Molecules; 2022 May; 27(10):. PubMed ID: 35630534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors.
    Del Prato S; Chilton R
    Diabetes Obes Metab; 2018 Apr; 20(4):786-799. PubMed ID: 29171700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.